Investors Purchase High Volume of GSK Call Options (NYSE:GSK)

GSK plc (NYSE:GSKGet Rating) was the target of some unusual options trading activity on Tuesday. Traders purchased 21,713 call options on the stock. This represents an increase of 86% compared to the average daily volume of 11,681 call options.

GSK Stock Performance

GSK stock opened at $33.85 on Wednesday. GSK has a 1-year low of $28.47 and a 1-year high of $46.97. The firm has a market cap of $68.84 billion, a P/E ratio of 4.15, a P/E/G ratio of 1.16 and a beta of 0.67. The firm has a 50-day moving average of $31.40 and a 200-day moving average of $37.15. The company has a current ratio of 0.97, a quick ratio of 0.74 and a debt-to-equity ratio of 2.22.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 12th. Investors of record on Friday, November 18th will be paid a $0.3695 dividend. This represents a $1.48 dividend on an annualized basis and a yield of 4.37%. The ex-dividend date of this dividend is Thursday, November 17th. GSK’s payout ratio is currently 15.20%.

Hedge Funds Weigh In On GSK

Institutional investors have recently bought and sold shares of the stock. Two Sigma Investments LP increased its stake in shares of GSK by 351.5% during the third quarter. Two Sigma Investments LP now owns 7,137,574 shares of the pharmaceutical company’s stock valued at $210,059,000 after purchasing an additional 5,556,832 shares in the last quarter. Two Sigma Advisers LP boosted its stake in shares of GSK by 1,007.7% during the 3rd quarter. Two Sigma Advisers LP now owns 4,511,412 shares of the pharmaceutical company’s stock worth $132,771,000 after acquiring an additional 4,104,146 shares during the last quarter. Armistice Capital LLC purchased a new position in shares of GSK during the 3rd quarter worth $105,948,000. JTC Employer Solutions Trustee Ltd raised its position in shares of GSK by 50.4% during the 1st quarter. JTC Employer Solutions Trustee Ltd now owns 9,016,970 shares of the pharmaceutical company’s stock valued at $392,735,000 after purchasing an additional 3,023,634 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its holdings in GSK by 32.5% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 9,621,370 shares of the pharmaceutical company’s stock valued at $419,107,000 after acquiring an additional 2,362,274 shares during the last quarter. 16.86% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on GSK shares. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 11th. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Thursday, September 8th. JPMorgan Chase & Co. cut their price target on shares of GSK from GBX 1,900 ($22.47) to GBX 1,600 ($18.92) in a research report on Tuesday, November 8th. Oddo Bhf upgraded shares of GSK from a “neutral” rating to an “outperform” rating in a research report on Thursday, September 29th. Finally, Credit Suisse Group upgraded shares of GSK from an “underperform” rating to a “neutral” rating in a report on Thursday, September 15th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $1,608.33.

About GSK

(Get Rating)

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Recommended Stories

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.